MV130 protects against viral respiratory infections through induction of Trained Immunity according to experimental study published in Cell Reports.

The study by Brandi et al. entitled “Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections” was carried out at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) under the direction of David Sancho, with the collaboration of INMUNOTEK.

The results demonstrate the ability of MV130 to protect against viral infections (influenza and vaccinia viruses), confirming recent results with MV130 against SARS-CoV-2. This study also demonstrates that this protection depends on the ability of MV130 to induce Trained Immunity. This type of immunity is long-lasting (it generates memory) and depends on epigenetic and metabolic changes that increase the responsiveness of the cells of the Innate Immune System.   This confers greater protection against different infections, including viral infections.

MV130 is an inactivated bacterial preparation developed by INMUNOTEK that meets the criteria for trained immunity-based vaccines (TIbV) and has proven clinical efficacy in preventing viral infections such as those that cause bronchiolitis in children.